Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
- Citation:
- J Clin Oncol vol 26 (15) 2457-63
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 799
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA02599, CA03927, CA11789, CA12046, CA16450, CA21060, CA31946, CA33601, CA37135, CA41287, CA45418, CA45808, CA47559, CA47577
- Corr. Author:
- Authors:
- Mark A Socinski A William Blackstock Jeffrey A Bogart Xiaofei Wang Michael Munley Julian Rosenman Lin Gu Gregory A Masters Peter Ungaro Arthur Sleeper Mark Green Antonius A Miller Everett E Vokes
- Networks:
- Study
- CALGB-30105
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Combined Modality Therapy, Deoxycytidine, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Paclitaxel, Placebos, Prognosis, Radiography, Radiotherapy Dosage, Radiotherapy, Conformal, Remission Induction, Survival Rate, Thoracic Neoplasms